Navamedic ASA (OSL:NAVA)

Market Cap	474.83M +29.9%
Revenue (ttm)	565.36M +6.4%
Net Income	-23.54M
EPS	-1.24
Shares Out	23.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,102
Average Volume	11,710
Open	20.00
Previous Close	19.80
Day's Range	19.80 - 20.20
52-Week Range	17.10 - 27.90
Beta	0.23
RSI	41.30
Earnings Date	Mar 25, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.